🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting over 82 million instances each year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Global Access

As per findings released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which involves an injection and a pill. The research involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to license and sell the drug in numerous regions with limited resources.

Doctors directly involved have voiced positive views. Having a easy-to-administer therapy such as this is described as a "game-changer" for managing the epidemic. This is considered crucial to alleviate the strain of the disease for patients and to prevent the spread of extremely resistant gonorrhoea globally.